Stereochemistry | ABSOLUTE |
Molecular Formula | C10H16N2O4S3.ClH |
Molecular Weight | 360.901 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
InChI
InChIKey=OSRUSFPMRGDLAG-QMGYSKNISA-N
InChI=1S/C10H16N2O4S3.ClH/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16;/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16);1H/t6-,8-;/m0./s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C10H16N2O4S3 |
Molecular Weight | 324.44 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Dorzolamide is a sulfonamide and a highly specific carbonic anhydrase II (CA-II) inhibitor, which is the main CA isoenzyme involved in aqueous humor secretion. Dorzolamide is marketed under the trade name Trusopt, indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It
catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic
acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic
anhydrase II (CA-II), found primarily in red blood cells (RBCs), but also in other tissues. Inhibition of
carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably
by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The
result is a reduction in intraocular pressure (IOP).
TRUSOPT Ophthalmic Solution contains dorzolamide hydrochloride, an inhibitor of human carbonic
anhydrase II. Following topical ocular administration, TRUSOPT reduces elevated intraocular pressure.
Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and
glaucomatous visual field loss.
Originator
Approval Year
Doses
AEs
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Tox targets
Sourcing
PubMed
Patents
Sample Use Guides
Usual Adult Dose for Intraocular Hypertension
One drop in the affected eye(s) three times a day
Usual Adult Dose for Glaucoma (Open Angle)
One drop in the affected eye(s) three times a day
Applies to the following strength(s): 2%
Route of Administration:
Topical